株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国の医薬品市場予測:2017〜2027年

Chinese Pharmaceutical Market Forecast 2017-2027

発行 Visiongain Ltd 商品コード 229860
出版日 ページ情報 英文 253 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=155.54円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
中国の医薬品市場予測:2017〜2027年 Chinese Pharmaceutical Market Forecast 2017-2027
出版日: 2017年09月18日 ページ情報: 英文 253 Pages
概要

中国の医薬品市場は2016年に1,454億米ドルに達しました。中でも心血管治療分野は市場の13.6%のシェアをもっています。同市場は今後2027年にかけCAGR12.3%で拡大すると予測されています。

当レポートでは、中国の医薬品市場について調査し、今後の収益予測、治療分野別動向、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 当レポートの概要

第2章 中国の医療:概要

第3章 中国の医薬品市場:議論と予測

  • 世界第2位の市場
  • 収益予測

第4章 中国の医療治療ニーズ

  • 疾患罹患率
  • 疾患死亡率

第5章 主な治療分野

  • 概要
  • 主な治療分野予測
  • 感染症治療薬
  • 心血管治療薬
  • 抗癌剤
  • 感染症治療薬
  • 糖尿病治療薬
  • 呼吸器疾患治療薬
  • 中枢神経系治療薬
  • 免疫調整剤

第6章 主要製品クラス

  • 概要
  • 製品クラス予測
  • 小分子
  • 漢方
  • 生物製剤

第7章 主要薬剤タイプ

  • 概要
  • 主力薬剤の成長予測
  • ジェネリック薬の市場独占
  • 処方箋
  • OTC薬
  • 特許取得済処方薬

第8章 販売チャンネル

第9章 主要企業

第10章 定性分析

第11章 結論

目次
Product Code: PHA0238

Title:
CHINESE PHARMACEUTICAL MARKET FORECAST 2017-2027
Cardiovascular Diseases, Oncology, Respiratory Diseases, Infectious Diseases, Diabetes, CNS, Autoimmune Diseases, Hypertension, Dyslipidaemia, COPD, Asthma, Antidepressants, Small Molecules, Branded Drugs, Traditional Chinese Medicine, Biologics, Vaccines, Biosimilars, Generic Prescription Drugs, Over-the-Counter Drugs, Patented Prescription Drugs, Hospitals, Retail Pharmacies, Grassroots Clinics.

The Chinese Pharmaceutical market is expected to grow at a CAGR of 12.3% in the second half of the forecast period. The Chinese Pharmaceutical market reached $145.4bn in 2016, dominated by the Cardiovascular therapy area which held 13.6% share of the market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 253-page report you will receive 68 tables and 90 figures- all unavailable elsewhere.

The 253-page report provides clear detailed insight into the Chinese Pharmaceutical market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Chinese Pharmaceutical market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by therapy area:
    • Cardiovascular: including specific revenue forecasts for Hypertension and Dyslipidaemia
    • Anticancer
    • Infectious Diseases
    • Diabetes
    • Respiratory: including specific revenue forecasts for Asthma and COPD
    • Central Nervous System: including specific revenue forecasts for Antidepressants
    • Autoimmune
    • Others

This report lists and discusses the domestic pharmaceutical companies that dominate each submarket. Moreover, this report discusses the drivers and restraints of each submarket.

  • This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by leading product class:
    • Small Molecules: further broken down into Generics Drugs and Branded Drugs
    • Traditional Chinese Medicine
    • Biologics: further broken down into Biologics (branded), Vaccines and Biosimilars

This report lists and discusses the domestic pharmaceutical companies that dominate each submarket. Moreover, this report discusses the drivers and restraints of each submarket.

  • This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by leading type of drug:
    • Generic Prescription Drugs
    • Over-the-Counter (OTC) Drugs
    • Patented Prescription Drugs

This report lists and discusses the domestic pharmaceutical companies that dominate each submarket.

  • This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by sales channel:
    • Hospitals
    • Retail Pharmacies
    • Grassroots Clinics

This report lists and discusses the domestic pharmaceutical companies that dominate each submarket.

  • This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT) that influence the Chinese Pharmaceutical Market. It also analyses social, technological, economic and political factors (STEP) that influence the Chinese Pharmaceutical Market
  • Our study ranks and provides 2016 revenues as well as market share of the top 50 domestic Chinese Pharmaceutical companies and top 10 Multinational Pharmaceutical Companies that are the major players in the Chinese Pharmaceutical Market
  • Our study lists and discusses the leading domestic and multinational Contract Research Organizations (CRO) that dominate the Chinese Pharmaceutical Market.

Visiongain's study is intended for anyone requiring commercial analyses for the Chinese Pharmaceutical market. You find data, trends and predictions.

Buy our report today Chinese Pharmaceutical Market Forecast 2017-2027: Cardiovascular Diseases, Oncology, Respiratory Diseases, Infectious Diseases, Diabetes, CNS, Autoimmune Diseases, Hypertension, Dyslipidaemia, COPD, Asthma, Antidepressants, Small Molecules, Branded Drugs, Traditional Chinese Medicine, Biologics, Vaccines, Biosimilars, Generic Prescription Drugs, Over-the-Counter (OTC) Drugs, Patented Prescription Drugs, Hospitals, Retail Pharmacies, Grassroots Clinics, Domestic Pharmaceutical Companies, Multinational Pharmaceutical Companies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. The Chinese Pharmaceutical Market, 2017-2027
  • 1.2. Chinese Pharmaceutical Market: Segmentation, 2017
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Main Questions Answered by This Analytical Study
  • 1.6. Who is This Report For?
  • 1.7. Methods of Research and Analysis
  • 1.8. Frequently Asked Questions(FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Chinese Healthcare: Overview, 2017

  • 2.1. China: Demographic Indicators Overview, 2017
  • 2.2. Chinese Healthcare System: Overview, 2017
  • 2.3. Analysis of China's Healthcare Expenditure
  • 2.4. The Chinese System: Who Really Pays the Bill?
  • 2.5. State Bodies Regulating the Chinese Pharmaceutical Market
  • 2.6. Healthy China 2020: The Government's Long-term Plan
  • 2.7. Analysis of the Potential of ‘Healthy China Initiative', 2017
  • 2.8. The Big Debate About Healthcare Funding

3. Chinese Pharmaceutical Market: Discussions and Predictions, 2017-2027

  • 3.1. Chinese Pharmaceutical Market: The Second Biggest Market in the World, 2016
  • 3.2. Chinese Pharmaceutical Market: Overall Revenue Forecast, 2017-2027

4. Medical Treatment Needs in China, 2017-2027

  • 4.1. Disease Prevalence in China, 2017-2027
  • 4.2. Disease Mortality Rates in China
    • 4.2.1. Top 5 Broad Causes of Death in China

5. Chinese Pharmaceutical Market: Leading Therapeutic Areas, 2017-2027

  • 5.1. Leading Therapeutic Areas in the Chinese Pharmaceutical Market: Overview, 2016
  • 5.2. Chinese Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2017-2027
  • 5.3. Chronic Diseases Overtook the Infectious Diseases Segment, 2017-2027
  • 5.4. Expanding China's EDL: New Blockbusters for 2017
  • 5.5. Cardiovascular Therapeutic Segment: Overview, 2017
    • 5.5.1. Cardiovascular Drugs Market: Forecast, 2017-2027
    • 5.5.2. Hypertension in China Reaches Unprecedented Levels
    • 5.5.3. Chinese Hypertension Drugs Market Continuing to Thrive: Forecast, 2017-2027
    • 5.5.4. Chinese Hypertension Drugs Market: Leading Products
    • 5.5.5. Treatment of Chinese Hypertensive Patients
    • 5.5.6. Dyslipidaemia: Overview of China's Most Prevalent Disease
    • 5.5.7. Treatment of Dyslipidaemia Affected by Reimbursement Issues
    • 5.5.8. Chinese Dyslipidaemia Market Prospects: Forecast, 2017-2027
    • 5.5.9. Chinese Cardiovascular Disease Segment: Major Focus of Western Companies
    • 5.5.10. Big Pharma Companies Dominate the Chinese Hypertension Drugs Market
    • 5.5.11. Increasing Domestic Company Presence in the Cardiovascular Therapeutic Segment
    • 5.5.12. Drivers and Restraints for the Chinese Cardiovascular Drugs Market, 2017
  • 5.6. Anticancer Therapeutic Segment: Overview, 2017
    • 5.6.1. Anticancer Drugs will be the Largest Segment of the Chinese Pharmaceutical Market by 2027: Forecast, 2017-2027
    • 5.6.2. Cancer Incidence Boosts the Eminence of China's Anticancer Drugs Market
    • 5.6.3. Targeted Anticancer Therapeutics Making Progress in China
    • 5.6.4. Chinese Pharma Companies Focusing on Anticancer Drugs
    • 5.6.5. Eli Lilly and Innovent Biologics' Strategic Alliance: New Big Player in China's Anticancer Market?
    • 5.6.6. Improved Healthcare Coverage for Cancer Patients Promises Strong Revenue Stream from Anticancer Drugs
    • 5.6.7. Marketing Innovative Anticancer Drug in China - Example from Roche
    • 5.6.8. Negative Impact of Late Cancer Diagnosis
    • 5.6.9. Cost of Treatment Critical for the Choice of Anticancer Medicine
    • 5.6.10. Tailored Anticancer Treatment for the Chinese Market - Notable Companies and their Developments
    • 5.6.11. Biomarker Testing in China - What Improvement is Possible?
    • 5.6.12. Drivers and Restraints for the Anticancer Drugs Segment, 2017
  • 5.7. Infectious Disease Therapeutics: Overview, 2017
    • 5.7.1. Infectious Disease Drugs Market: Forecast, 2017-2027
    • 5.7.2. What Makes China Prominent for Antibiotics Use: Analysis of Cephalosporin, 2016
    • 5.7.3. China's Infectious Disease Market Dominated by Domestic Companies
    • 5.7.4. Antibiotics Over-use Reported in China: Causes and Results
    • 5.7.5. HIV and Hepatitis in China: Viread Added to EDL in 2017
    • 5.7.6. Hepatitis C Drug Challenges
    • 5.7.7. Drivers and Restraints for the Infectious Diseases Pharma Segment, 2017
  • 5.8. Diabetes Therapeutic Segment: Overview, 2017
    • 5.8.1. Diabetes Drugs Market: Forecast, 2017-2027
    • 5.8.2. Multinational Companies in the Chinese Diabetes Drug Market: Overview and Analysis, 2017
    • 5.8.3. Domestic Companies Competing in the Chinese Diabetes Drug Market
    • 5.8.4. Diabetes in China: Challenges and Opportunities
    • 5.8.5. Drivers and Restraints for the Diabetes Drugs Segment, 2017
  • 5.9. Respiratory Therapeutic Segment: Overview, 2017
    • 5.9.1. Respiratory Disease Drugs Market: Forecast, 2017-2027
    • 5.9.2. Chinese COPD Market: How Profitable Could It Be?
    • 5.9.3. Chinese COPD Treatments Market: Predicted Revenue Increase - Forecast, 2017-2027
    • 5.9.4. Chinese Asthma Drugs Market to Give Dependable Growth: Forecast, 2017-2027
    • 5.9.5. Domestic Respiratory Drug Producers
    • 5.9.6. Leading Respiratory Disease Drugs in China
    • 5.9.7. AstraZeneca Sustains Market Penetration through Collaboration and Research
    • 5.9.8. Drivers and Restraints for the Respiratory Diseases Segment, 2017
  • 5.10. Central Nervous System(CNS) Therapeutics: Overview, 2017
    • 5.10.1. CNS Drugs Market: Forecast, 2017-2027
    • 5.10.2. By 2027, 8 Million People in China will Suffer from Depression
    • 5.10.3. Depression Drugs Market in China will Reach a 25% Annual Growth Rate: Forecast, 2017-2027
    • 5.10.4. Domestic Companies in China's CNS Disorders Market
    • 5.10.5. China's Aging Population: Driver for the CNS Segment
    • 5.10.6. Rise of Dementia and Alzheimer's Disease Presents Strong Market Opportunity
    • 5.10.7. High Demand for Pain Relief Medicines in China
    • 5.10.8. Drivers and Restraints for the CNS Drugs Segment, 2017
  • 5.11. Immunomodulators: Overview, 2017
    • 5.11.1. Autoimmune Drugs Market: Forecast, 2017-2027
    • 5.11.2. Notable Chinese Companies in the Immunomodulators Market
    • 5.11.3. Challenges Erode the Immunomodulators Market's Potential
    • 5.11.4. Immunomodulator Treatments to Gain Momentum in China
    • 5.11.5. Drivers and Restraints for the Autoimmune Drugs Segment, 2017

6. Chinese Pharmaceutical Market: Leading Product Classes, 2017-2027

  • 6.1. Product Classes in the Chinese Pharmaceutical Market: Overview, 2016
  • 6.2. Chinese Pharmaceutical Market: Product Classes Forecasts, 2017-2027
  • 6.3. Small Molecules: Overview, 2017
    • 6.3.1. Chinese Small Molecule Drugs Market: Forecast, 2017-2027
    • 6.3.2. Generics: Growth Engine for the Small Molecules Segment
    • 6.3.3. Healthcare Reform Provides Opportunities for Original-Branded and Generic Drugs
    • 6.3.4. Drivers and Restraints for the Small Molecule Treatments Market in China, 2017
  • 6.4. Traditional Chinese Medicine(TCM): Overview, 2017
    • 6.4.1. Traditional Chinese Medicine Market: Forecast, 2017-2027
    • 6.4.2. Investments in TCM Development: Analysis of China's TCM Market, 2017
    • 6.4.3. Expansion of the TCM Market
    • 6.4.4. Leading Chinese Companies in the TCM Segment, 2017
    • 6.4.5. Drivers and Restraints for the Traditional Chinese Medicines Market, 2017
  • 6.5. Chinese Biological Drugs Market: Overview, 2016
    • 6.5.1. Chinese Biologics Market: Forecasts, 2017-2027
    • 6.5.2. Branded Biologics Perform Well in China: Forecast, 2017-2027
    • 6.5.3. Biomedicines Set for Strategic Growth: Analysis of China's Fastest Growing Product Class, 2017
    • 6.5.4. Roche Finding a Way Forward in China with Branded Biologics
    • 6.5.5. Chinese Vaccines Market: Overview, 2016
    • 6.5.6. China: The World's Fifth Largest Vaccine Market
    • 6.5.7. Chinese Vaccines Segment Loses Share: Forecast, 2017-2027
    • 6.5.8. Companies Dominating the Vaccines Market in China
    • 6.5.9. Domestic Manufacturer Supplies 80% of Vaccines in China
    • 6.5.10. Multinational Companies Compete for a Share of the Chinese Vaccines Market
    • 6.5.11. Hepatitis B Vaccine in China - a Story of Success
    • 6.5.12. Chinese Biosimilars Market: Overview, 2016
    • 6.5.13. Chinese Biosimilars Market: Forecast, 2017-2027
    • 6.5.14. A Boost for Biosimilars? Pfizer Set up a New Chinese Manufacturing Facility
    • 6.5.15. Chinese Biosimilar Development Guidelines Released in 2015
    • 6.5.16. Leading Chinese Biosimilar Manufacturers
    • 6.5.17. Market Access for Biosimilars: Critical to Leverage Opportunities in China
    • 6.5.18. Drivers and Restraints of the Chinese Biologics Market

7. Chinese Pharmaceutical Market: Leading Drug Types, 2017-2027

  • 7.1. Drug Types in the Chinese Market: Overview, 2016
  • 7.2. Growth Forecasts for Leading Drug Types in China, 2017-2027
  • 7.3. Generic Drugs Dominate the Chinese Pharmaceutical Market
  • 7.3. Generic Prescription Drugs Market in China: Forecast, 2017-2027
    • 7.3.1. Chinese Pharmaceutical Market Structure Favours Generics' Sales
    • 7.3.2. Which Drugs Benefit More from the Government's Healthcare Reform: Original-Patented or Generic?
    • 7.3.3. Many Chinese Patients Favour Branded Generics
    • 7.3.4. AstraZeneca and Pfizer: Leaders in the Chinese Branded Generics Market
  • 7.4. Chinese Over-the-Counter Medicines Market: Forecast, 2017-2027
    • 7.4.1. Chinese OTC Drugs Segment: Insights and Analysis of the Market's Potential, 2016
    • 7.4.2. China: The World's Biggest OTC Pharmaceuticals Market
    • 7.4.3. Leading Domestic Companies in the Chinese OTC Market, 2017
    • 7.4.4. Bayer: The Biggest Multinational Player in China's OTC Market
  • 7.5. Chinese Patented Prescription Drugs Market: Forecast, 2017-2027
    • 7.5.1. Online Sales Prohibited in 2016: A Big Blow to the Market?

8. Chinese Pharmaceutical Market: Sales Channels, 2017-2027

  • 8.1. Chinese Pharmaceutical Market: Sales Channels Overview and Value, 2016
  • 8.2. Chinese Pharmaceutical Market: Sales Channels Forecasts, 2017-2027
  • 8.3. Only Five Domestic Companies Have a Sizable Share of the Chinese Pharma Distribution Market
  • 8.4. Chinese Distribution Channels are Highly Fragmented Compared to Western Counterparts
  • 8.5. Chinese Distribution Channels: Why Consolidation is Essential?
  • 8.6. Shift Towards Consolidation within the Distribution Chain: Key Market Developments
  • 8.7. China's Drugs Distribution Environment: Issues and Challenges
  • 8.8. Chinese Distribution Value Chain Follows a Complex Model
  • 8.9. Chinese Pharmaceutical Distribution Network Comprises the World's Largest Sales Force
  • 8.10. Bribery Penalties: Indication of China's Changing Pharmaceutical Distribution Practices
  • 8.11. Hospital Sales Channels: Forecast, 2017-2027
    • 8.11.1. Hospitals: Foundation of the Chinese Healthcare System
    • 8.11.2. Chinese Public Hospitals: Healthcare Reform's Priority
    • 8.11.3. How does the Medicines Mark-up Ban Affect Hospitals' Revenues?
  • 8.12. Retail Pharmacies Channels: Forecast, 2017-2027
    • 8.12.1. Difficulties in Retail Pharmacy Market Estimates
    • 8.12.2. Online Sale Prohibition May Affect the Distribution of Revenue Within the Market
  • 8.13. Grassroots Clinics' Sales Channels: Forecast, 2017-2027
    • 8.13.1. Rural Investment Will Facilitate Drug Sales Growth in Grassroots Clinics
  • 8.14. Other Sales Channels: Forecast, 2017-2027
    • 8.14.1. Other Sales Channels: The Grey Pharmaceuticals in China

9. Leading Companies in the Chinese Pharmaceuticals Market, 2016

  • 9.1. Top 50 Domestic Chinese Pharmaceutical Companies, 2016
  • 9.2. China's Pharma is Highly Fragmented Compared to Other Prominent Markets
  • 9.3. Leading Chinese Contract Research Organizations
  • 9.4. Leading Multinational Companies in the Chinese Pharmaceutical Market: Strategies that Win, 2017
    • 9.4.1. MNC Revenue and Market Share Estimates, 2016
    • 9.4.2. AstraZeneca and Pfizer: Leaders in the Chinese Branded Generics Segment
    • 9.4.3. Bayer - Exceeds $3bn of Pharma Sales in China
    • 9.4.4. Pfizer's Strategic Approach in China - Does it Work?
    • 9.4.5. Multinational Contract Research Organizations in China
  • 9.5. New Policies Shift the Market Dynamics for Leading Players
  • 9.6. Emerging Strategies to Boost Drug Sales and Comply with Regulations
  • 9.7. What is Next in China for Multinational Pharma Companies?
  • 9.8. Drivers and Restraints for Big Pharma's Sales Growth in China, 2017

10. Qualitative Analysis of the Chinese Pharmaceutical Market, 2017

  • 10.1. Strengths: Increasing Investment in the Healthcare System
    • 10.1.1. As the Disease Burden Grows, So Does GDP
    • 10.1.2. Chinese Pharmaceutical Market Still Has Untapped Potential
    • 10.1.3. Progressive Urbanization Continues to Drive Healthcare Spending
    • 10.1.4. New Policies Recognize the Importance of IP
    • 10.1.5. Research Hub for Asia Pacific and Beyond
  • 10.2. Weaknesses: Imbalance of Resources and Quality Challenges
    • 10.2.1. Healthcare Quality Issues Hit the Chinese Pharmaceutical Market
    • 10.2.2. Highly Fragmented Pharmaceutical Market
    • 10.2.3. Reimbursement and Market Access
    • 10.2.4. Limited First-Class Laboratory Facilities Reported
    • 10.2.5. Regulations and Clinical Trial Research
  • 10.3. Opportunities: Quickly Emerging Volume Growth
    • 10.3.1. Tailored Strategies to Meet the Chinese Pharma Market's Need
    • 10.3.2. Portfolio Diversification Matters
    • 10.3.3. Enhancing Consolidation Activities
    • 10.3.4. Innovative Biotechnology Sector
    • 10.3.5. Liberal Regulations on Stem Cells Research
  • 10.4. Threats: What if Things Go Wrong in China?
    • 10.4.1. Strong Government Intervention
    • 10.4.2. Anhui Model and its Results
  • 10.5. Social Forces: The Increasing Power of China's Demographics
    • 10.5.1. The Ageing Dragon
    • 10.5.2. The Obesity Epidemic
    • 10.5.3. Social Changes and Their Effect on China's Shifting Medical Treatment Patterns
  • 10.6. Technological Factors: Embracing Technology and Increasing R&D Capabilities
    • 10.6.1. National Database and Telemedicine: New Trends Shaping the Industry
    • 10.6.2. Developing China's R&D Capabilities through Technology
    • 10.6.3. China Has the World's Largest and Most Affordable Genomic Sequencing Facilities
  • 10.7. Economic Factors: Economic Growth Closely Related to the Chinese Pharmaceutical Market Growth
    • 10.7.1. China's Rise as an Economic Superpower
    • 10.7.2. Underlying Problems of China's Economic Growth
    • 10.7.3. How Many Five-Year Plans Will Follow?
  • 10.8. Political: The Chinese Government Possesses the Ultimate Power

11. Conclusions

  • 11.1. China's Healthcare Reform: Crucial Factor for Pharmaceutical Market Growth
  • 11.2. China: The Country Driving Growth for the World's Pharmaceutical Market, 2017-2027
  • 11.3. Cancer Will Form a Main Therapeutic Segment in the Chinese Pharmaceutical Market in 2027
  • 11.4. Generic and OTC Drugs Set to Remain the Main Product Types, but Patented Drugs Will Experience Momentum
  • 11.5. Pharmacy Sales are the Next Big Market Opportunity in China
  • 11.6. Domestic Companies Still Dominate the Chinese Pharma Market, Amid Increasing Competition from MNCs
  • 11.7. Concluding Thoughts on the Research and Analysis

Appendices

  • Visiongain Report Sales Order Form
  • About Visiongain
  • Associated Visiongain Reports
  • Visiongain report evaluation form

List of Tables

  • Table 2.1: China: Demographic Indicators, 2006-2016
  • Table 2.2: Healthcare Expenditure: Leading Markets and BRIC Countries, Total(%) of GDP, 2006-2014
  • Table 2.3: Out-of-pocket Health Expenditures in China:(%) of Private Spending on Healthcare, 2006-2014
  • Table 2.4: Chinese Institutions Regulating the Pharmaceutical and Healthcare Industries in China, 2017
  • Table 3.1: Chinese Pharmaceutical Market Overall Forecast: Market Size($bn), Annual Growth Rate(%), CAGR(%), 2017-2027
  • Table 4.1: Top 5 Causes of Death per(000s) in China's Urban and Rural Areas, 2016
  • Table 5.1: Chinese Pharmaceutical Market by Therapy Area: Market Size($bn), Market Share(%), 2016
  • Table 5.2: Chinese Pharmaceutical Market by Therapy Area: Forecast Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 5.3: Chinese Pharmaceutical Market by Therapy Area: Market Share Forecast(%), 2017-2027
  • Table 5.4: Selected High Profile Drugs: China's Essential Drugs List
  • Table 5.5: Chinese Cardiovascular Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 5.6: Chinese Hypertension Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), CAGR(%), 2017-2027
  • Table 5.7: Chinese Hypertension Market by Drug Class: Market Size($bn), Market Share(%), 2016
  • Table 5.8: Chinese Dyslipidaemia Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), CAGR(%), 2017-2027
  • Table 5.9: Top Companies in the Chinese Hypertension Market: Revenue($bn), Market Share(%), 2016
  • Table 5.10: Leading Domestic Chinese Cardiovascular Drug Manufacturers and Their Activities, 2017
  • Table 5.11: Chinese Anticancer Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 5.12: Selected Domestic Chinese Anticancer Drug Manufacturers and Their Activities, 2017
  • Table 5.13: Chinese Infectious Disease Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 5.14: Chinese Infectious Disease Drugs Market by Drug Class: Market Size($bn), Market Share(%), 2016
  • Table 5.15: Domestic Antibacterial Drug Manufacturers and Their Activities, 2017
  • Table 5.16: Chinese Diabetes Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 5.17: Selected Domestic Chinese Diabetes Drug Manufacturers and Their Activities, 2017
  • Table 5.18: Chinese Respiratory Disease Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 5.19: Chinese COPD Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), CAGR(%), 2017-2027
  • Table 5.20: Chinese Asthma Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), CAGR(%), 2017-2027
  • Table 5.21: Selected Domestic Companies in the Respiratory Market and Their Activities, 2017
  • Table 5.22: Chinese Respiratory Drug Market by Product Class: Sales($bn), Market Share(%), 2016
  • Table 5.23: Chinese CNS Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 5.24: Chinese Antidepressants Market Forecast: Market Size($bn), Annual Growth Rate(%), 2017-2027
  • Table 5.25: Selected Domestic Companies in the CNS Market and Their Activities, 2017
  • Table 5.26: Chinese Autoimmune Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 5.27: Selected Chinese Immunomodulator Drug Companies and Their Activities, 2017
  • Table 6.1: Chinese Pharmaceutical Market by Product Class: Market Size($bn), Market Share(%), 2016
  • Table 6.2: Chinese Pharmaceutical Market by Product Class: Forecast Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 6.3: Chinese Small Molecule Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 6.4: Chinese Small Molecule Drugs Market by Product Type: Forecast Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 6.5: Traditional Chinese Medicine Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 6.6: Selected TCM Manufacturers and their Activities, 2017
  • Table 6.7: Chinese Biological Drugs Market by Product Type: Forecast Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 6.8: Chinese Branded Biologics Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 6.9: Chinese Vaccines Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 6.10: Chinese Biosimilars Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 6.11: Selected Chinese Biosimilar Manufacturers and Their Product Lines, 2017
  • Table 7.1: Chinese Pharmaceutical Market by Drug Type: Market Size($bn), Market Share(%), 2016
  • Table 7.2: Chinese Pharmaceutical Market by Drug Type: Forecast Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 7.3: Chinese Generic Prescription Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 7.4: Chinese Over-the-Counter Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 7.5: Selected Chinese OTC Drug Manufacturers and Their Activities, 2017
  • Table 7.6: Chinese Patented Prescription Drugs Market Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 8.1: Hospital Channels Market Size($bn), Market Share(%), 2016
  • Table 8.2: Chinese Pharmaceutical Market by Sales Channel: Market Size($bn), Market Share(%), 2016
  • Table 8.3: Chinese Pharmaceutical Market by Sales Channel: Forecast Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 8.4: Chinese Hospital Sales of Pharmaceuticals Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 8.5: Chinese Retail Pharmacy Sales of Pharmaceuticals Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 8.6: Chinese Grassroots Clinics Sales of Pharmaceuticals Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 8.7: Chinese Pharmaceuticals Sales Through Other Channels Forecast: Market Size($bn), Annual Growth Rate(%), Market Share(%), CAGR(%), 2017-2027
  • Table 9.1: Top 50 Domestic Chinese Pharmaceutical Companies: Rank(1-25), Revenue($bn), Market Share(%), 2016
  • Table 9.2: Top 50 Domestic Chinese Pharmaceutical Companies: Rank(26-50), Revenue($bn), Market Share(%), 2016
  • Table 9.3: Selected Domestic Contract Research Organizations and Their Activities, 2017
  • Table 9.4: Selected Multinational Pharmaceutical Companies in the Chinese Market and Their Activities, 2017
  • Table 9.5: Selected Multinational Pharmaceutical Companies in the Chinese Market and Their Activities(Continued), 2017
  • Table 9.6: Selected Multinational Pharmaceutical Companies in the Chinese Market and Their Activities(Continued), 2017
  • Table 9.7: Top 10 Multinational Pharmaceutical Companies in the Chinese Pharmaceutical Market: Revenue($bn), Market Share(%), 2016
  • Table 11.1: Summary of the Chinese Pharmaceutical Market by Product Class: Market Size($bn), Market Share(%), CAGR(%), 2016, 2022, 2026
  • Table 11.2: Summary of the Chinese Pharmaceutical Market by Therapy Class: Market Size($bn), Market Share(%), CAGR(%), 2016, 2022, 2027
  • Table 11.3: Summary of Chinese Pharmaceutical Sales Channels: Market Size($bn), Market Share(%), CAGR(%), 2016, 2022, 2027

List of Figures

  • Figure 1.1: Chinese Pharmaceutical Market Segmentation, 2017
  • Figure 2.1: Healthcare Expenditure Per Capita PPP: Leading Markets and BRIC Countries,($bn)
  • Figure 2.2: Out-of-pocket Health Expenditures in China:(%) of Private Spending on Healthcare, 2006-2014
  • Figure 3.1: Chinese Pharmaceutical Market: Value Chain, 2017
  • Figure 3.2: Chinese Pharmaceutical Market Forecast: Market Size($bn), 2017-2027
  • Figure 3.3: Chinese Pharmaceutical Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 4.1: Top 5 Broad Causes of Death in China Urban Areas, 2016
  • Figure 4.2: Top 5 Broad Causes of Death in China Rural Areas, 2016
  • Figure 5.1: Chinese Pharmaceutical Market by Therapy Area: Market Size($bn), 2016
  • Figure 5.2: Chinese Pharmaceutical Market by Therapy Area: Market Share(%), 2016
  • Figure 5.3: Chinese Pharmaceutical Market by Therapy Area: Market Share(%), 2022
  • Figure 5.4: Chinese Pharmaceutical Market by Therapy Area: Market Share(%), 2027
  • Figure 5.5: Chinese Cardiovascular Disease Market: Segmentation by Drug Class, 2017
  • Figure 5.6: Chinese Cardiovascular Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.7: Chinese Cardiovascular Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.8: Chinese Hypertension Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.9: Chinese Hypertension Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.10: Chinese Hypertension Market by Drug Class: Market Share(%), 2016
  • Figure 5.11: Chinese Dyslipidaemia Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.12: Chinese Cardiovascular Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.13: Chinese Cardiovascular Drugs Market: Drivers and Restraints, 2017-2027
  • Figure 5.14: Chinese Anticancer Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.15: Chinese Anticancer Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.16: Chinese Anticancer Drugs Market: Drivers and Restraints, 2017-2027
  • Figure 5.17: Chinese Infectious Disease Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.18: Chinese Infectious Disease Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.19: Chinese Antibacterial Drugs Market by Drug Class: Market Share(%), 2016
  • Figure 5.20: Chinese Infectious Disease Drugs Market: Drivers and Restraints, 2017-2027
  • Figure 5.21: Chinese Diabetes Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.22: Chinese Diabetes Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.23: Chinese Diabetes Drugs Market: Drivers and Restraints, 2017-2027
  • Figure 5.24: Chinese Respiratory Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.25: Chinese Respiratory Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.26: Chinese COPD Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.27: Chinese COPD Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.28: Chinese Asthma Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.29: Chinese Asthma Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.30: Chinese Respiratory Disease Drugs Market: Drivers and Restraints, 2017-2027
  • Figure 5.31: Chinese CNS Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.32: Chinese CNS Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.33: Chinese Antidepressant Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.34: Chinese Antidepressant Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.35: Chinese CNS Drugs Market: Drivers and Restraints, 2017-2027
  • Figure 5.36: Chinese Autoimmune Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 5.37: Chinese Autoimmune Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 5.38: Chinese Autoimmune Drugs Market: Drivers and Restraints, 2017-2027
  • Figure 6.1: Chinese Pharmaceutical Market by Product Class: Market Size($bn), 2016
  • Figure 6.2: Chinese Pharmaceutical Market by Product Class: Market Size($bn), 2017-2027
  • Figure 6.3: Chinese Pharmaceutical Market by Product Class: Market Size(%), 2016
  • Figure 6.4: Chinese Small Molecule Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 6.5: Chinese Small Molecule Drugs Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 6.6: Chinese Small Molecule Drugs Market: Drivers and Restraints, 2017-2027
  • Figure 6.7: Traditional Chinese Medicine Market Forecast: Market Size($bn), 2017-2027
  • Figure 6.8: Traditional Chinese Medicine Market Forecast: Annual Growth Rate(%), 2017-2027
  • Figure 6.9: Traditional Chinese Medicine Market: Drivers and Restraints, 2017-2027
  • Figure 6.10: Chinese Biologics Market Forecast: Market Size($bn), 2017-2027
  • Figure 6.11: Chinese Biologics Market Forecast: Annual Growth(%), 2017-2027
  • Figure 6.12: Chinese Branded Biologics Market Forecast: Market Size($bn), 2017-2027
  • Figure 6.13: Chinese Branded Biologics Market Forecast: Annual Growth(%), 2017-2027
  • Figure 6.14: Chinese Vaccines Market Forecast: Market Size($bn), 2017-2027
  • Figure 6.15: Chinese Vaccines Market Forecast: Annual Growth(%), 2017-2027
  • Figure 6.16: Chinese Biosimilars Market Forecast: Market Size($bn), 2017-2027
  • Figure 6.17: Chinese Biosimilars Market Forecast: Annual Growth(%), 2017-2027
  • Figure 6.18: Chinese Biologics Market: Drivers and Restraints, 2017-2027
  • Figure 7.1: Chinese Pharmaceutical Market by Drug Type: Market Size($bn), 2016
  • Figure 7.2: Chinese Pharmaceutical Market by Drug Type: Market Share(%), 2016
  • Figure 7.3: Chinese Generic Prescription Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 7.4: Chinese Generic Prescription Drugs Market Forecast: Annual Growth(%), 2017-2027
  • Figure 7.5: Chinese Over-the-Counter Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 7.6: Chinese Over-the-Counter Drugs Market Forecast: Annual Growth(%), 2017-2027
  • Figure 7.7: Chinese Patented Prescription Drugs Market Forecast: Market Size($bn), 2017-2027
  • Figure 7.8: Chinese Patented Prescription Drugs Market Forecast: Annual Growth(%), 2017-2027
  • Figure 8.1: Hospital Channels Market Size($bn), Market Share(%), 2016
  • Figure 8.2: Chinese Pharmaceutical Market by Sales Channel: Market Size($bn), 2016
  • Figure 8.3: Chinese Pharmaceutical Market by Sales Channel: Market Share(%), 2016
  • Figure 8.4: Chinese Pharmaceutical Market by Sales Channels: Revenue Forecasts($bn), 2017-2027
  • Figure 8.5: Fragmented Nature of the Chinese Pharmaceutical Distribution Market: Market Share(%) by Revenue($bn) for the Leading Five Distributors, 2016
  • Figure 8.6: Chinese Hospital Sales of Pharmaceuticals Market Forecast: Market Size($bn), 2017-2027
  • Figure 8.7: Chinese Hospital Sales of Pharmaceuticals Forecast: Annual Growth(%), 2017-2027
  • Figure 8.8: Chinese Retail Pharmacy Sales of Pharmaceuticals Forecast: Market Size($bn), 2017-2027
  • Figure 8.9: Chinese Retail Pharmacy Sales of Pharmaceuticals Forecast: Annual Growth(%), 2017-2027
  • Figure 8.10: Chinese Grassroots Clinics Sales of Pharmaceuticals Forecast: Market Size($bn), 2017-2027
  • Figure 8.11: Chinese Grassroots Clinics Sales of Pharmaceuticals Forecast: Annual Growth(%), 2017-2027
  • Figure 8.12: Chinese Pharmaceuticals Sales Through Other Channels Forecast: Market Size($bn), 2017-2027
  • Figure 8.13: Chinese Pharmaceuticals Sales Through Other Channels Forecast: Market Size($bn), 2017-2027
  • Figure 9.1: Top 10 Multinational Pharmaceutical Companies in the Chinese Pharmaceutical Market: Revenue($bn) Chinese Pharma Market, 2016
  • Figure 9.2: Chinese Pharmaceutical Market: Drivers and Restraints for MNCs' Growth, 2017-2027
  • Figure 11.1: Summary of the Chinese Pharmaceutical Market by Product Class: Market Size($bn), 2016, 2022, 2027
  • Figure 11.1: Summary of the Chinese Pharmaceutical Market by Therapy Class: Market Size($bn), 2016, 2022, 2027
  • Figure 11.2: Summary of the Chinese Pharmaceutical Sales Channels: Market Size($bn), 2016, 2022, 2027

Companies Listed:

  • 3SBio
  • Acambis
  • Agilent
  • Alibaba Group
  • Alliance Boots
  • Amerisource-Bergen
  • Amgen
  • Anhui Anke Biotech
  • AppTech Laboratory Services
  • Asian Cancer Research Group
  • Astellas
  • AstraZeneca
  • Asymchem Laboratories
  • AXM Pharma
  • Baxter
  • Bayer
  • Bayer Healthcare
  • BeiGene
  • Beijing Four Rings Bio-pharmaceutical
  • Beijing Genomics Institute
  • Beijing Kexing Bioproducts
  • Beijing Key Yuan Xinhai Pharmaceutical
  • Beijing SL Pharmaceutical
  • Beijing Taiyang
  • Beijing Tiantan Biological Products
  • Beijing Tong Ren Tang
  • Bio-Bridge Science
  • BiODura
  • Bloomberg
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Buchang Pharma
  • Cardinal Health
  • CASiGEN Pharma
  • Celgene
  • Celsion Corp
  • Changzhou Qianhong Biopharma
  • Chemizon(Beijing) Pharma-Tech
  • Chengdu Di'ao Pharmaceutical Group
  • Chengdu Institutes of Biological Products
  • Chiesi Edding Hong Kong Limited
  • Chi-Med
  • China Chemical & Pharmaceutical Group
  • China National Accord
  • China National Biotec Group
  • China National Pharmaceutical Group
  • China NT Pharma Group
  • China Pharmaceutical Commerce Association
  • China Pharmaceutical Quality Management Association
  • China Resources Double-Crane Pharmaceuticals
  • China Resources Sanjiu Medical
  • China Shineway Pharmaceutical
  • China Traditional Chinese Medicine Co.
  • ChinaBio Group
  • ChinaGate
  • Chonqqing Taiji Industry
  • Cipla
  • Consun Pharmaceutical Group
  • Cord Blood America
  • Covance
  • CSPC Pharmaceutical Group
  • Daan Gene
  • Daiichi Sankyo
  • Dalian Hissen Bio-Pharm
  • Dawnrays Pharmaceutical Holdings
  • Dihon Pharmaceutical Group
  • Dongsheng Pharmaceutical
  • Dr. Reddy's Laboratories
  • Egret
  • Eisai
  • Eli Lilly
  • Excel PharmaStudies
  • FeRx Incorporated
  • Financial Times
  • Foshan City
  • Furen Pharmaceutical Group
  • Gan & Lee Pharmaceutical
  • Genentech
  • GeneScience Pharmaceuticals
  • Gilead Sciences
  • GlaxoSmithKline
  • Goldman Sachs
  • Guangdong BeiKang Pharmaceutical
  • Guangdong Techpool
  • Guangxi Wuzhou Zhongheng Group
  • Guangzhou Medical University
  • Guangzhou Pharma
  • Guangzhou Pharmaceutical Corporation
  • Guizhou Baiqiang Pharmaceutical
  • Hangzhou East China Pharmaceutical Group
  • Hangzhou Jiuyuan Gene Engineering
  • Hangzhou Tigermed Consulting
  • Hangzhou Zhongmei Huadong Pharmaceutical
  • Harbin Pharmaceutical Group
  • Harbin Tri-Lion Pharmaceutical
  • Harvard University
  • HD Biosciences
  • Henan Lingrui Pharmaceutical
  • Hengrui
  • Henlius Biopharmaceuticals
  • HitGen
  • Hua Medicine
  • Huadong Medicine
  • Hualan Biological Engineering
  • Hualida Biotech
  • Hutchinson Whampoa
  • Hutchison MediPharma
  • i3 Research
  • ICON
  • Inner Mongolia Yili Energy
  • Innovent Biologics
  • JD.com(Jindong Mall)
  • JHL Biotech
  • Jiangsu Chia-tai Tianqing Pharmaceutical
  • Jiangsu Hansen Pharmaceutical
  • Jiangsu Hansoh Pharmaceutical
  • Jiangsu Hengrui Medicine
  • Jiangsu Nhwa Pharmaceutical
  • Jilin Extrawell Changbaishan
  • Jilin Province Huinan Changlong
  • Jinling Pharmaceutical
  • Johnson & Johnson
  • Joincare Pharma
  • JOINN Laboratories
  • Kangmei Pharmaceutical
  • KPC Pharmaceuticals
  • Lepu Medical
  • Livzon Pharmaceutical Group
  • Lundbeck
  • Lundbeck Institute
  • Massachusetts Institute of Technology
  • McKesson
  • Merck & Co.
  • Merck Sharp & Dohme
  • Microport Medical
  • Mycenax
  • Mylan
  • Nanjing Kanghai Pharmaceutical
  • Nanjing Pharmaceutical Factory
  • Nestle Health Sciences
  • Nestle SA
  • Newsummit Biopharma
  • North China Pharmaceutical Group
  • Northeast Pharmaceutical Group(NEPG)
  • Novartis
  • Novast Laboratories
  • Novo Nordisk
  • Oncobiologics
  • Otsuka
  • Pfizer
  • Pharmaceutical Product Development LLC
  • Pharmaron
  • PKU Healthcare Group
  • Qilu Pharmaceutical
  • Quintiles
  • Roche
  • Sanofi
  • Schering-Plough
  • Servier
  • Shandong Dong-E E-Jiao
  • Shandong Kexing Bioproducts
  • Shanghai Celgen Bio-Pharmaceutical
  • Shanghai Charity Foundation
  • Shanghai CP Guojian Pharmaceuticals
  • Shanghai DND Pharm-Technology
  • Shanghai Fosun Pharmaceutical Group
  • Shanghai Furen Industrial
  • Shanghai Institutes of Biological Sciences
  • Shanghai Jinhe Bio-Technology
  • Shanghai Pharmaceuticals Holding
  • ShangPharma
  • Shenzhen Heapalink
  • Shenzhen Kangtai Biological Products
  • Shenzhen Neptunus Bioengineering
  • Shenzhen Salubris Pharmaceuticals
  • Shenzhen Wenle('Main Luck') Pharmaceutical
  • Shijiazhuang Pharmaceutical Group
  • Shijiazhuang Yiling
  • Shineway Pharmaceutical Group
  • Sichuan Jiufeng Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • Sichuan Yuanda Shuyang Pharmaceutical
  • Sihuan Pharmaceutical Holdings
  • Simcere Pharmaceutical
  • SiniWest Holdings
  • Sino Biological
  • Sino Biopharmaceutical
  • Sinopharm
  • State Key Lab of Respiratory Disease
  • Sundia MediTech
  • Sundiro Pharma
  • Swiss Re
  • Symbio Pharmaceuticals
  • Takeda
  • Tangshan Yian Bioengineering
  • Tasly Pharmaceuticals
  • Teva
  • The Financial Times
  • Thermo Fisher Scientific
  • Tianjin Jin Yao Group
  • Tianjin Kinnovata Pharmaceutical Company
  • Tonghua Dongbao
  • United Pharmatech
  • Vectura
  • Venturepharm Laboratories
  • Vertex Pharmaceuticals
  • Viva Biotech
  • Wai Yuen Tong Medicine Holdings
  • Walmart Holdings
  • Wanbang Biopharmaceuticals
  • Weigao Holding
  • Winteam Pharmaceutical Group
  • WuXi AppTec
  • Xiamen Amoytop Biotech
  • Xian-Janssen Pharmaceuticals
  • Xiuzheng Pharmaceutical
  • Xizang Haisco
  • Yabao Pharmaceutical Group
  • Yangtze River Pharmaceuticals
  • Youcare Pharmaceutical Group
  • Yunnan Baiyao
  • Zai Lab
  • Zendex Bio Strategy
  • Zensun(Shanghai) Sci & Tech
  • Zhejiang Beta Pharma
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang Medicine
  • Zhejiang Tianyuan
  • Zhenjian Hisun Pharmaceuticals
  • Zhuhai United States Labs
  • Zuellig Pharma China

List of Organizations Mentioned in the Report:

  • China Food and Drug Administration(CFDA)
  • China Academy of Chinese Medical Sciences
  • Chinese Academy of Sciences(CAS)
  • Chinese Center for Drug Evaluation
  • Chinese Ministry of Commerce
  • Diabetes Society
  • Ministry of Commerce of the People's Republic of China
  • Ministry of Health of the People's Republic of China
  • Ministry of Labor and Social Security of the People's Republic of China
  • National Development and Reform Commission
  • National Institute for the Control of Pharmaceutical and Biological Products
  • Northwest University
  • Shandong University
  • State Traditional Chinese Medicine Administration
  • The World Bank
  • University of Warwick
  • US Food and Drug Administration
  • Washington University
  • WHO World Health Organization
  • WTO World Trade Organization
Back to Top